Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact of Grape Consumption on Brain Metabolism and Cognitive Function

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by University of California, Los Angeles.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Daniel H. Silverman, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01573611
First received: April 5, 2012
Last updated: April 6, 2012
Last verified: April 2012
  Purpose

Constituents of grapes have been studied for their antioxidant, anti-inflammatory, and anticarcinogenic properties. In the past decade, there has been emerging evidence regarding a potential role for grapes in slowing cognitive decline and other effects of aging. Furthermore, evidence has been obtained in vivo that supplementation of aged rats with grape seed extract improves cognitive performance. Despite the promising accumulating data supporting the use of grapes as a safe and effective strategy for delaying the incidence of dementia, it remains unclear how grape intake would be useful with respect to factors such as dose schedule or stage of dementing illness. In general, well-controlled experimental data obtained in human subjects is in need of much further development. The investigators aim to measure effects of grape intake on cerebral metabolism and cognitive function, and to determine whether initial patterns, and magnitude of change, of cerebral metabolism assessed by positron emission tomography (PET) can serve respectively as a predictor of, and biomarker for, the magnitude of cognitive changes resulting from intake of grapes.


Condition Intervention Phase
Mild Cognitive Impairment
Dietary Supplement: Grape Powder
Dietary Supplement: Placebo Powder
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Examining the Impact of Grape Consumption on Brain Metabolism and Cognitive Function in Patients With Mild Cognitive Impairment

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • Change from baseline in neuropsychological (cognitive, functional) test results [ Time Frame: baseline and 6 months ] [ Designated as safety issue: Yes ]
  • Change from baseline in regional cerebral metabolism [ Time Frame: baseline and 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 12
Study Start Date: April 2012
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Grape Powder Dietary Supplement: Grape Powder
36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
Placebo Comparator: Placebo Powder Dietary Supplement: Placebo Powder
36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months

Detailed Description:

People experiencing mild cognitive changes represent an epidemiologically major segment of the geriatric patient population. Numerous studies have been carried out to study the benefits of grapes associated with dementia and Alzheimer's disease (AD). In the present proposal, the investigators aim to determine 1) whether cognitive and regional cerebral metabolic changes associated with grape powder use can be identified, 2) if the presence and magnitude of therapeutic responses to grape in patients having mild cognitive decline can be predicted by particular patterns of regional brain metabolism, and 3) for any changes identified, the magnitude of those changes that correlate with the magnitude of the changes noted in the neuropsychologic parameters will be examined, which might be useful as an objective biomarker for therapeutic effect. A total of 12 patients suffering from documented decline of cognitive function (in the absence of overt dementia) will be studied. In this placebo-controlled, double-blinded study, the 12 recruited subjects who have met the screening criteria will be randomized to receive 72 g of grape powder per day or placebo. The subjects will undergo a baseline brain PET study with the radiotracer [F - 18] fluorodeoxyglucose (FDG). In addition, neuropsychological assessments will be performed at baseline and six months after initiation of therapy. Follow-up PET scans will also be obtained at six months to assess the changes in metabolism occurring with each therapy regimen.

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cognitive deficit and/or personality change is present, as observable by physician and/or close contact(s) of the patient; or in the absence of this, the patient provides a clear history of decline which the patient's physician deems to be reliable.
  • If history or neurologic exam reveals findings suspicious for stroke, tumor, bleed, ictal activity, or hydrocephalus, then CT/MRI and appropriate neurological or neurosurgical consultation must have been obtained.
  • Standard history, physical, and laboratory screen have been performed to identify possible presence of depression, substance abuse, malnourishment, medication effects and interactions, cardiopulmonary compromise, electrolyte/calcium imbalance, anemia, hypoxemia, infection, thyroid dysfunction, renal dysfunction, hepatic dysfunction, or glucose dysregulation.
  • Any positive findings revealed in 2) or 3) above have been appropriately treated, wherever possible, but cognitive/behavioral deficit persists post-therapy.

Exclusion Criteria:

  • Subjects under age 65 will not be recruited, in order to enhance the clinical relevance of the project by focusing on the age groups in whom serious concerns about early signs and symptoms of senile onset dementia are most typically emerging.
  • Already diagnosed with Alzheimer's disease or other cause of dementia
  • Cognitive dysfunction has impaired subject's ability to perform activities of daily living.
  • Present or past history of thyroid disease (due to effects of both the disease and thyroid hormone replacement therapy on brain metabolism that we and others have begun to identify, but which remain incompletely characterized.)
  • Claustrophobia or metal in body or other condition that would preclude PET or MRI from being acquired, or visual, auditory or motor deficits that would preclude accurate neuropsychological testing.
  • Currently receiving medication used specifically to treat Alzheimer's disease or other dementia-related disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01573611

Contacts
Contact: Daniel H. Silverman, MD, Ph.D. 310-825-4257 dsilver@ucla.edu
Contact: Kelsey Pomykala 310-794-5067 kpomykala@mednet.ucla.edu

Locations
United States, California
UCLA Medical Center Recruiting
Los Angeles, California, United States, 90095-6942
Contact: Daniel H. Silverman, MD, Ph.D.    310-825-4257    dsilver@ucla.edu   
Contact: Kelsey Pomykala    310-794-5067    kpomykala@mednet.ucla.edu   
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Daniel H. Silverman, MD, Ph.D. University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Daniel H. Silverman, Professor, Molecular and Medical Pharmacology, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01573611     History of Changes
Other Study ID Numbers: 11002966
Study First Received: April 5, 2012
Last Updated: April 6, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:
mild cognitive impairment
dementia
positron emission tomography (PET)
F-18 Fluorodeoxyglucose (FDG)
cerebral metabolism
dietary supplement

Additional relevant MeSH terms:
Cognition Disorders
Mild Cognitive Impairment
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on November 23, 2014